Thinking of Moving to the U.S. to Work in Pharma? Think Again

For decades, the US has been the holy grail for ambitious scientists and pharma professionals. Big pharma HQs, cutting edge biotech hubs, fat salaries, career prestige. If you wanted to make it big in drug development, medical affairs, or clinical research, you booked your ticket for Boston or New Jersey.

But hold up. If you’re thinking about making that move now, you need to hit pause. The H-1B visa, the bread and butter pathway for foreign talent in US pharma, just got way more expensive and complicated thanks to new restrictions pushed through by Donald Trump’s administration.

The $100K Roadblock

Here’s the bombshell: as of September 21, 2025, employers filing a new H-1B application must pay a $100,000 fee. That’s not a typo. One hundred thousand dollars upfront.

Before, fees were in the low thousands. Now, it’s a six figure barrier to entry. It doesn’t apply if you already hold an H-1B or are just renewing, but for new applicants, it’s a game changer.

Yes, there are exemptions. Doctors and medical residents might dodge the fee under a “national interest” clause. But if you’re in medical affairs, regulatory, or commercial roles? It’s a grey zone, and you’d need to make a compelling case.

Why This Matters for Pharma Careers

Pharma companies love global talent. Clinical development, regulatory submissions, data science, these are skills in short supply in the U.S. But let’s be real: $100K per head is going to make employers think twice.

• Big Pharma can absorb it: Pfizer, Novartis, J&J can stomach the fee for high value hires.

• Smaller biotechs can’t: Start ups and mid sized firms may back away from sponsoring new H-1Bs.

• You’ll need to stand out: Employers will reserve sponsorship for candidates they can’t live without.

The result? Less opportunity, more competition, and a lot of uncertainty about whether your role qualifies as “essential.”

What Are Your Options?

If you’re still set on a US move, here’s the playbook:

• Target big companies: They’re the most likely to sponsor despite the cost.

• Build your “national interest” case: If your work touches unmet medical needs, rare disease research, or public health, emphasize that impact.

• Look at cap exempt organizations: Universities, hospitals, and non profits aren’t bound by the same H-1B lottery and might be less affected.

• Consider alternative visas: O-1 (for “extraordinary ability”), EB green card routes, or company sponsored L-1 transfers if you’re already in a multinational.

• Don’t sleep on other hubs: Canada, the UK, Switzerland, and Singapore are aggressively courting pharma talent while the U.S. throws up walls.

The Bigger Picture

This isn’t just about individuals. It’s about the future of US pharma innovation. Cutting off talent pipelines means slowing down drug development, limiting diverse perspectives, and potentially ceding ground to countries that are more welcoming.

So if you’re a pharma professional abroad, the message is clear: the US door isn’t closed, but it’s a lot narrower and more expensive to walk through. Think carefully before you uproot your life, because what used to be a straightforward career move now comes with a six figure price tag your employer may not want to pay.

---

The US is still the biggest player in pharma, but these new barriers make it less of a no brainer. If you’re planning your next career leap, you’ve got to be strategic, or consider if your skills might go further in places that actually want you there.